Target Validation Information
TTD ID	T23347
Target Name	Interleukin 1 receptor type 2 (IL1R2)
Type of Target	Clinical trial
Action against Disease Model	AMG 108	Drug Info	IL-1 receptor (IL-1R) blockage was highly efficacious in reducing inflammation, both in acute and advanced stages. In antigen-induced arthritis, cartilage damage, erosion progression, and propagation of inflammation are dependent on IL-1. In a recent study of immune complex arthritis, IL-1-deficient mice were strongly protected. In a novel transgenic mouse model of adjuvant arthritis, a pure T-cell model, mice deficient in the IL-1R antagonist displayed uncontrolled IL-1 activity and developed spontaneous T-cell-dependent autoimmune arthritis	[1]
References
REF 1	A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis. Arthritis Res Ther. 2010;12(5):R192.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.